(lp0
S'ACADIA Pharmaceuticals Inc Risk Points versus Health Care CML News - 20 hours ago This is a scatter plot analysis of the critical risk points from the option market for ACADIA Pharmaceuticals Inc  compared to its own past and the Health Care ETF.State Street Corp Boosts Stake in ACADIA Pharmaceuticals Inc.  - Chaffey BreezeThe Short Interest in ACADIA Pharmaceuticals Inc.  Declines By 9.4% - Petro Global News 24'
p1
aS"ACADIA Pharma Looks Like A Take-Out Target Seeking Alpha - Feb 27, 2017 But one company in particular has this San Diegan very interested. The company I'm talking about is ACADIA Pharmaceuticals , and in a field of speculative, pre-FDA-approval pharma companies, ACADIA has potential few others possess."
p2
aS"Analyst's Proposition on Skechers USA, Inc. , ACADIA Pharmaceuticals Inc ... The USA Commerce - 16 hours ago Latest closing price was 12.14% above its 50-day moving average and 15.21% above its 200-day moving average. On 03/27/2017 close, ACADIA Pharmaceuticals Inc.  rose 2.35% to $35.65. The stock currently has a Market Cap of $4.32B."
p3
aS"Don't Be So Sure ACADIA Wants To Sell Seeking Alpha - Mar 7, 2017 I have owned for myself and the Clients of Mott Capital Management, LLC shares of ACADIA Pharmaceuticals  for well over two years now.ACADIA Pharmaceuticals Inc  Has A Problem With Nuplazid - BNL Finance   ACADIA Pharmaceuticals Inc. : What's the Story? - StockNewsJournal"
p4
aS'ACADIA: A Buyout Remains Most Likely Scenario Seeking Alpha - Mar 3, 2017 ACADIA Pharmaceuticals has surged ahead some 80% over the past year thanks to the FDA approval of Nuplazid, the first drug to be approved for the psychosis associated with Parkinsons.'
p5
aS'Earnings Reaction History: ACADIA Pharmaceuticals Inc, 50.0% Follow-Through ... Nasdaq - Feb 28, 2017 ACADIA Pharmaceuticals Inc  is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement ...'
p6
aS'Trading Update on Shares of ACADIA Pharmaceuticals Inc.  Rives Journal - 10 hours ago Individual investors might be studying multiple metrics in order to maximize returns. ACADIA Pharmaceuticals Inc.  presently has a Gross Margin  ratio of 0.023033.'
p7
aS'Iceberg Ahead With Valeant Pharmaceuticals Intl Inc  Weak Guidance ... Smarter Analyst - Mar 1, 2017 Valeant Pharmaceuticals Intl Inc  has Canaccord worried after releasing 2017 financial guidance yesterday morning that came up short of already subdued expectations.'
p8
aS'ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and ... Yahoo Finance - Feb 28, 2017 ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system  disorders, today announced its financial&nbsp;...'
p9
aS"Analyst's Predictions on ACADIA Pharmaceuticals Inc. , Santander ... StockNewsJournal - Mar 20, 2017 ROI deals with the invested cash in the company and the return the investor realize on that money based on the net profit of the business."
p10
a.